ROTH Financials 07/16/2014 13:17:04 PharmaRoth La
Post# of 50
Posted On: 07/16/2014 2:17:00 PM
ROTH Financials 07/16/2014 13:17:04
PharmaRoth Labs, Inc.
Period Ending Jun 30, 2013 Jun 30, 2012
Total Revenue 154 605
Cost of Revenue 120 462
Gross Profit 34 143
Operating Expenses
Research and Development - -
Sales, General and Admin. 461 312
Non-Recurring Items - -
Other - -
Operating Income (427) (169)
Income From Continuing Operations
Add'l Income/Expense Items - 8
Earnings Before Interest and Tax (427) (161)
Interest Expense - -
Earnings Before Tax (427) (161)
Income Tax - -
Minority Interest (2) (1)
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (425) (160)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (425) (160)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (425) (160)
PharmaRoth Labs, Inc.
Period Ending Jun 30, 2013 Jun 30, 2012
Total Revenue 154 605
Cost of Revenue 120 462
Gross Profit 34 143
Operating Expenses
Research and Development - -
Sales, General and Admin. 461 312
Non-Recurring Items - -
Other - -
Operating Income (427) (169)
Income From Continuing Operations
Add'l Income/Expense Items - 8
Earnings Before Interest and Tax (427) (161)
Interest Expense - -
Earnings Before Tax (427) (161)
Income Tax - -
Minority Interest (2) (1)
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (425) (160)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (425) (160)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (425) (160)
(0)
(0)PharmaRoth Labs, Inc. (ROTH) Stock Research Links
Scroll down for more posts ▼